Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • edgeR and MA-plot question

    Hi,

    I am running edgeR and used plotSmear to visualize my results. When coloring only the genes that are DE by FDR<0.05 I see that many genes have a higher fold change than some of the DE genes and that some of the DE genes have a low fold change. This is only the case when I use estimateGLMTagwiseDisp and not when I use estimateGLMCommonDisp. Does this mean that using common dispersion is the best? I only have cases and controls in my data so I guess it should be good enough but I always thought estimating tagwise dispersion was better?

    Also:
    It also seems like ~90 % of my genes are up-regulated. I tried all the different normalization options but the results seem to be the same. Can this be true or could something be wrong with my data? Any way of testing that?
    Last edited by moem; 11-18-2015, 05:57 AM.

  • #2
    I can't comment on your edgeR problem but maybe try using limma and see if a different approach gives the same result.

    Regarding 90% up-regulated, what are the differences between your cases and controls? For example, were they sequenced at the same time, extracted at the same time, etc.

    Comment


    • #3
      Does it make biological sense?

      Is the condition you are comparing between cases and controls one where you might expect the majority of the genes to be upregulated?

      Comment


      • #4
        Thank you for your answers. I have run limma and DESeq now and it gives the same sort of answers with regards to the amount of up/down-regulation.

        I was wondering if anyone could see if my code makes sense:

        condition <- relevel(factor(input$condition),ref=”Control”)
        design <- model.matrix(~condition)

        “design” then lists “Intercept” and “ConditionCase”.

        e <- DGEList(counts=countstable)
        e <- calcNormFactors(e, method=”TMM”)
        e <- estimateGLMCommonDisp(e, design)
        e <- estimateGLMTrendedDisp(e, design)
        e <- estimateGLMTagwiseDisp(e, design)
        efit <- glmFit(e, design)
        efit <- glmLRT(efit, coef="ConditionCase")

        The logFCs are then mainly positive. My interpretation is then up-regulation in ConditionCase.
        Last edited by moem; 11-24-2015, 12:42 AM.

        Comment


        • #5
          The result seems reasonable.

          Is there any other reason you can think of that might cause systematic up regulation?

          Were controls and treatments extracted at the same time? Sequenced at the same time? Are there age differences between treatments? Sex differences between treatments?

          Comment


          • #6
            Thanks for looking at my code.

            Can't think of any reasons, but this is not a condition I know much about.

            Extraction and sequencing at the same time and same sex. No systematic difference in age between groups.

            Comment

            Latest Articles

            Collapse

            • seqadmin
              Essential Discoveries and Tools in Epitranscriptomics
              by seqadmin




              The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...
              04-22-2024, 07:01 AM
            • seqadmin
              Current Approaches to Protein Sequencing
              by seqadmin


              Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
              04-04-2024, 04:25 PM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by seqadmin, Today, 08:47 AM
            0 responses
            12 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 04-11-2024, 12:08 PM
            0 responses
            60 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 04-10-2024, 10:19 PM
            0 responses
            59 views
            0 likes
            Last Post seqadmin  
            Started by seqadmin, 04-10-2024, 09:21 AM
            0 responses
            54 views
            0 likes
            Last Post seqadmin  
            Working...
            X